Cheshire, UK -- (MARKET WIRE) -- January 11, 2007 -- London, UK; Brentwood, TN, US; 11 January 2007 - Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today provides an update on progress with Voraxaze™ in the United States and Europe. Voraxaze™ is an adjunctive therapy for patients experiencing, or at risk of, toxicity from methotrexate (“MTX”), a widely used anti-cancer agent.
